Dr. Ron Najafi, CEO of NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, http://www.novabaypharma.com), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, will present at the Maxim Group Growth Conference. The conference will be held at the Grand Hyatt New York Hotel in New York City on Tuesday, October 7, 2008. NovaBay’s presentation is scheduled to begin at 1:30 PM EDT.
The Maxim Group Growth Conference will feature interactive presentations from over eighty companies, as well as one-on-one meetings with executives from the healthcare, technology and other emerging growth sectors. Attendees will include securities analysts, fund managers, and institutional investors. The presentation will be webcast live and will be accessible online at http://www.wsw.com/webcast/maxim/nby/.
Dr. Najafi will provide a corporate overview and review NovaBay’s business development strategy and product development candidates in the areas of hospital infections, catheter-associated urinary tract infections, and dermatology. NovaBay has a collaboration agreement with the leading eye care company in the world, Alcon Laboratories, Inc., to research, develop, and commercialize the company’s Aganocide® compounds to treat eye, ear, and sinus infections, as well as contact lens solution. NovaBay has also partnered with Kinetic Concepts, Inc. (KCI), to develop an anti-infective solution for use with KCI’s wound healing system. NovaBay has also recently announced positive results from a Phase IIa study of AgaNase for the nasal decolonization of Staph, including MRSA. The company is also developing product candidate opportunities for the dermatology market, details of which Dr. Najafi will provide during the presentation.
About Maxim Group
Maxim Group is a full-service investment banking, securities and investment management firm headquartered in New York. The Firm provides an array of financial services including: investment banking, equity research, private wealth management, structured products, and global institutional equity, fixed-income and derivative sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals. For additional information, please visit http://www.maximgrp.com.
NovaBay Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, which are based upon small molecules that are generated by white blood cells to defend the body against invading pathogens. NovaBay believes that Aganocide® compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of not only bacterial and viral infections, but also Staphylococcus aureus (including resistant strains known as MRSA) without developing resistance, a serious problem that invariably plagues all antibiotics. NovaBay has entered into a licensing and research collaboration agreement with Alcon Laboratories, Inc. for use of the Aganocide® compounds in the eye, ear and sinus, and in contact lens solutions. The company also has a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay’s NeutroPhase product in wound care applications.
NovaBay™, Aganocide®, AgaNase™, and NeutroPhase™ are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
NovaBay Pharmaceuticals Contacts
Head of Investor Relations
The Investor Relations Group
Adam Holdsworth / Erica Ruderman / Brett Foley
Janet Vasquez / Laura Colontrelle